Evidence map›Paper›PMID 39252626›Full record

ReviewCurrent molecular medicine2025

The AMPK/cAMP Metabolic Signaling Axis as a Possible Therapeutic Target for Diabetes.

José Augusto Nogueira-Machado, Nathália Augusta Gomes, Fabiana Rocha-Silva

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

José Augusto Nogueira-MachadoPrograma de Pós-Graduação Stricto Sensu em Medicina/Biomedicina, Faculdade de Saúde Santa Casa de BH, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0002-8257-6585
Nathália Augusta GomesDepartment of Morphology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0002-7089-309X
Fabiana Rocha-SilvaPrograma de Pós-Graduação Stricto Sensu em Medicina/Biomedicina, Faculdade de Saúde Santa Casa de BH, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0003-2698-9649

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a complex disease, despite the availability of numerous treatments, its progression and complications can only be mitigated and managed to a certain extent. After the onset, diabetes cannot be reversed. Its global expansion makes it challenging for governments to control the considerable costs of treating people with diabetes. Many studies have been carried out by widely recognized pharmaceutical companies that are considering the development of new drugs for diabetic treatments. Diets, sedentary habits, and lifestyles that are currently prevalent have an enormous influence on the global spread of diabetes. The tools available to clinicians for therapy do not solve the problem. It is known that a patient, when diagnosed, would already have had diabetes for more than three years. Studies on diabetes signaling consider the effects of hyperglycemia but also highlight the roles of insulin receptor activation and resistance. Understanding the intricate signaling network and its interactions with hyperglycemiainduced pathways is crucial. In this context, the cyclic AMP/AMPK axis emerges as a promising therapeutic target for diabetes. However, there is a noticeable lack of literature exploring the metabolic network induced by hyperglycemia and its interconnected pathways. Therefore, investigating the cyclic cAMP/AMPK axis could provide valuable insights, given its complex connections with various metabolic pathways. This mini-review aims to delve into the metabolic signaling of the AMPK/cAMP axis in the context of diabetes, highlighting its metabolic interactions and potential implications.

Indexed as

AMP-Activated Protein KinasesCyclic AMPDiabetes MellitusSignal TransductionAnimalsHumansHyperglycemiaHypoglycemic AgentsMolecular Targeted TherapyAMP-Activated Protein KinasesCyclic AMPHypoglycemic AgentsAD.AMPKcAMPDiabetes mellitushyperglycemiametabolic signaling

Identifiers

PMID39252626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.